دورية أكاديمية
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study.
| العنوان: | Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. |
|---|---|
| المؤلفون: | Topless RK; Biochemistry Department, University of Otago, Dunedin, New Zealand., Gaffo A; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.; Birmingham Veteran Affairs Medical Center, Birmingham, AL, USA., Stamp LK; University of Otago Christchurch, Christchurch, New Zealand., Robinson PC; University of Queensland, Brisbane, QLD, Australia., Dalbeth N; Department of Medicine, University of Auckland, Auckland, New Zealand., Merriman TR; Biochemistry Department, University of Otago, Dunedin, New Zealand.; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA. |
| المصدر: | The Lancet. Rheumatology [Lancet Rheumatol] 2022 Apr; Vol. 4 (4), pp. e274-e281. Date of Electronic Publication: 2022 Jan 28. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Elsevier Ltd., [2019]- |
| مستخلص: | Background: There is a paucity of data on outcomes for people with gout and COVID-19. We aimed to assess whether gout is a risk factor for diagnosis of COVID-19 and COVID-19-related death, and to test for sex- and drug-specific differences in risk. Methods: We used data from the UK Biobank, which included 15 871 people with gout. We used multivariable-adjusted logistic regression in the following analyses using a case-control study design: to test for an association between gout and COVID-19 diagnosis in the entire UK Biobank cohort (n=459 837); to test for an association between gout and COVID-19-related death in people who were known to have died or survived with COVID-19 (n=15 772); to test for an association between gout and COVID-19-related death in the entire UK Biobank cohort (n=459 837); and to assess risk of COVID-19-related death in a subset of patients from the UK Biobank cohort with prescription data, stratified by prescription of urate-lowering therapy and colchicine (n=341 398). Models 1 and 2 were adjusted for age group, sex, ethnicity, Townsend deprivation index, BMI, and smoking status. Model 2 was also adjusted for diagnosis of 16 other diseases that are established comorbidities of gout or established risk factors for COVID-19-related death. Findings: Gout was associated with diagnosis of COVID-19 (odds ratio [OR] 1·20, 95% CI 1·11-1·29) but not with risk of COVID-19-related death in the cohort of patients diagnosed with COVID-19 (1·20, 0·96-1·51). In the entire cohort, gout was associated with COVID-19-related death (1·29, 1·06-1·56); women with gout had an increased risk of COVID-19-related death (1·98, 1·34-2·94), whereas men with gout did not (1·16, 0·93-1·45). We found no significant differences in the risk of COVID-19-related death according to prescription of urate-lowering therapy or colchicine. When patients with gout were stratified by vaccination status, the risk of diagnosis with COVID-19 was significant in the non-vaccinated group (1·21, 1·11-1·30) but not the vaccinated group (1·09, 0·65-1·85). Interpretation: Gout is a risk factor for COVID-19-related death in the UK Biobank cohort, with an increased risk in women with gout, which was driven by risk factors independent of the metabolic comorbidities of gout. Funding: Health Research Council of New Zealand. Competing Interests: PCR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, Janssen, Novartis, UCB Pharma, Roche, and Pfizer, meeting attendance support from BMS, Pfizer, and UCB Pharma, and grant funding from Janssen, Novartis, Pfizer, and UCB Pharma, all outside the submitted work. ND reports personal fees from AbbVie, Horizon, Janssen, Dyve Biosciences, Cello Health, PK Med, JW Pharmaceuticals, Selecta, Arthrosi, and AstraZeneca, grants from Amgen and AstraZeneca, and non-financial support from AbbVie, all outside the submitted work. LKS reports personal fees from the New Zealand PHARMAC Therapeutic Advisory Committee. All other authors declare no competing interests. (© 2021 Elsevier Ltd. All rights reserved.) |
| References: | Lancet Rheumatol. 2021 Feb;3(2):e131-e137. (PMID: 33392516) BMC Endocr Disord. 2021 May 8;21(1):97. (PMID: 33964922) Arthritis Rheum. 2007 Feb 15;57(1):109-15. (PMID: 17266099) Arthritis Rheumatol. 2019 Nov;71(11):1935-1942. (PMID: 31169353) Lancet Rheumatol. 2022 Apr;4(4):e237-e240. (PMID: 35156060) Lancet Respir Med. 2021 Dec;9(12):1419-1426. (PMID: 34672950) Mediators Inflamm. 2021 Feb 23;2021:6687412. (PMID: 33679237) Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463) Nature. 2021 May;593(7858):270-274. (PMID: 33723411) Lancet Rheumatol. 2021 May;3(5):e317-e318. (PMID: 33907738) Ann Rheum Dis. 2015 Apr;74(4):661-7. (PMID: 24431399) Arthritis Care Res (Hoboken). 2016 Dec;68(12):1894-1898. (PMID: 27014846) Ann Rheum Dis. 2021 May;80(5):660-666. (PMID: 33257496) Ann Rheum Dis. 2021 Jul;80(7):930-942. (PMID: 33504483) Lancet Rheumatol. 2021 Feb;3(2):e88-e90. (PMID: 33655223) Arthritis Rheumatol. 2019 Jun;71(6):991-999. (PMID: 30618180) ACR Open Rheumatol. 2021 May;3(5):333-340. (PMID: 33856739) Arthritis Res Ther. 2017 Aug 9;19(1):181. (PMID: 28793914) Lancet Rheumatol. 2020 Oct;2(10):e583-e585. (PMID: 33106791) BMJ. 2020 Aug 13;370:m3220. (PMID: 32816745) Lancet Respir Med. 2021 Aug;9(8):924-932. (PMID: 34051877) PLoS Med. 2015 Mar 31;12(3):e1001779. (PMID: 25826379) Br J Dermatol. 2021 Jul;185(1):80-90. (PMID: 33368145) Front Endocrinol (Lausanne). 2021 May 06;12:633767. (PMID: 34025575) Arthritis Rheumatol. 2021 Aug;73(8):e30-e45. (PMID: 34128356) N Z Med J. 2018 Nov 9;131(1485):8-12. (PMID: 30408813) |
| معلومات مُعتمدة: | MC_PC_17228 United Kingdom MRC_ Medical Research Council; MC_QA137853 United Kingdom MRC_ Medical Research Council |
| تواريخ الأحداث: | Date Created: 20220207 Latest Revision: 20231115 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8798088 |
| DOI: | 10.1016/S2665-9913(21)00401-X |
| PMID: | 35128470 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2665-9913 |
|---|---|
| DOI: | 10.1016/S2665-9913(21)00401-X |